• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Xilio Therapeutics, Inc. - Common Stock (NQ:XLO)

    1.150 +0.419 (+57.32%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Xilio Therapeutics, Inc. - Common Stock

    < Previous 1 2 Next >
    Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
    From Xilio Therapeutics, Inc.; AbbVie Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
    From Gilead Sciences, Inc.
    Via Business Wire
    Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
    From Xilio Therapeutics, Inc.; Gilead Sciences, Inc.
    Via GlobeNewswire
    Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.